Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study

Marit Synnestvedt1, Elin Borgen2, Erik Wist3,11, Gro Wiedswang4, Kjetil Weyde5, Terje Risberg6, Christian Kersten7, Ingvil Mjaaland8, Lise Vindi9, Cecilie Schirmer2, Jahn Martin Nesland10, and Bjørn Naume11*

Abstract

Background: Presence of disseminated tumor cells (DTCs) in bone marrow (BM) after completion of systemic adjuvant treatment predicts reduced survival in breast cancer. The present study explores the use of DTCs to identify adjuvant insufficiently treated patients to be offered secondary adjuvant treatment intervention, and as a surrogate marker for therapy response.

Methods: A total of 1121 patients with pN1-3 or pT1c/T2G2-3pN0-status were enrolled. All had completed primary surgery and received 6 cycles of anthracycline-containing chemotherapy. BM-aspiration was performed 8-12 weeks after chemotherapy (BM1), followed by a second BM-aspiration 6 months later (BM2). DTC-status was determined by morphological evaluation of immunocytochemically detected cytokeratin-positive cells. If DTCs were present at BM2, docetaxel (100 mg/m², 3qw, 6 courses) was administered, followed by DTC-analysis 1 month (BM3) and 13 months (BM4) after the last docetaxel infusion.

Results: Clinical follow-up (FU) is still ongoing. Here, the descriptive data from the study are presented. Of 1085 patients with a reported DTC result at both BM1 and BM2, 94 patients (8.7%) were BM1 positive and 83 (7.6%) were BM2 positive. The concordance between BM1 and BM2 was 86.5%. Both at BM1 and BM2 DTC-status was significantly associated with lobular carcinomas (p = 0.02 and p = 0.03, respectively; chi-square). In addition, DTC-status at BM2 was also associated with pN-status (p = 0.009) and pT-status (p = 0.03). At BM1 28.8% and 12.8% of the DTC-positive patients had ≥2 D TCs and ≥3 DTCs, respectively. At BM2, the corresponding frequencies were 47.0% and 25.3%. Of 72 docetaxel-treated patients analyzed at BM3 and/or BM4, only 15 (20.8%) had persistent DTCs. Of 17 patients with ≥3 DTCs before docetaxel treatment, 12 patients turned negative after treatment (70.6%). The change to DTC-negativity was associated with the presence of ductal carcinoma (p = 0.009).

Conclusions: After docetaxel treatment, the majority of patients experienced disappearance of DTCs. As this is not a randomized trial, the results can be due to effects of adjuvant (docetaxel/endocrine/trastuzumab) treatment and/or limitations of the methodology. The clinical significance of these results awaits mature FU data, but indicates a possibility for clinical use of DTC-status as a residual disease-monitoring tool and as a surrogate marker of treatment response.

Trial registration: Clin Trials Gov NCT00248703

* Correspondence: bna@ous-hf.no
11Department of Oncology, Oslo University Hospital, Oslo, Norway and K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway
Full list of author information is available at the end of the article

© 2012 Synnestvedt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
The introduction of systemic adjuvant therapy has improved the survival of patients with early breast cancer. However, there is a lack of established tools to measure the direct effect of a given systemic treatment on minimal residual disease/micrometastases after primary surgery.

Techniques for identification and characterization of disseminated tumor cells may open possibilities for prediction of treatment response and tailored treatment decisions. Immunocytochemical detection (ICC) of disseminated tumor cells (DTCs) in the bone marrow (BM) and further analyses of these cells have been introduced as means to meet these needs [1-9]. Moreover, presence of DTCs during relapse-free follow-up (+/- tamoxifen) has been found to be a strong predictor of systemic relapse and breast cancer death [10-12]. Similar results were also reported in two smaller studies analyzing DTC status in very high-risk breast cancer patients early after completion of chemotherapy [1,13]. The presence of DTCs after chemotherapy clearly indicates a rationale for testing of alternative (secondary) treatment approaches. Detection of DTCs following treatment intervention should also be further tested for potential value as a surrogate marker for future relapse/treatment effect. During the last decade, docetaxel has been established as a highly active treatment against breast cancer. Response rates of 40-50% have regularly been reported as a highly active treatment against breast cancer. During the last decade, docetaxel has been established as a highly active treatment against breast cancer. Response rates of 40-50% have regularly been reported as a highly active treatment against breast cancer.

Methods
Patients
A total of 1121 patients with node positive or high-risk node negative disease (pT1c/T2G2-3pN0) were enrolled in the period from October 2003 to May 2008 at 7 hospitals in Norway. All patients had completed primary surgery and 6 cycles of adjuvant anthracycline-containing chemotherapy (FEC: 5-FU 600 mg/m², epirubicin 60-100 mg/m² and cyclophosphamide 600 mg/m² 3qw). Patients between 18-70 years with no earlier or concomitant carcinoma (other than breast carcinoma), except for basal cell carcinoma of the skin and in situ cervix cancer, were eligible if they had completed staging analysis including chest X-ray, bone scintigraphy or MRI, liver ultrasound or liver CT scan, without presence of metastases. The study was approved by the Regional Ethical Committee (reference number S-03032). Written consent was obtained from all patients. The study is registered in Clin Trials Gov (registration number NCT00248703).

Patients with estrogen receptor (ER) and/or progesteron receptor (PR) positive tumors received endocrine treatment according to standard recommendations at the time of the study (tamoxifen for 5 years; tamoxifen for 2-3 years followed by aromatase inhibitor for 2-3 years for postmenopausal patients from 2005). From June 2005, patients with HER2-positive tumors received trastuzumab every 3rd week for 1 year. This treatment was started after completion of radiotherapy. No patients received bisphosphonates as adjuvant treatment.

Study design
The first BM-aspiration was performed at the end of radiation therapy or 8-12 weeks after standard adjuvant chemotherapy (BM1). A second BM-aspiration was performed 6 months later (BM2). Bone marrow was aspirated from posterior iliac crest bilaterally (5 ml from each site) in local anaesthesia. The processing of BM and method for DTC-analysis were performed as previously described [20]. If DTC-positive at BM2, the patient received docetaxel (100 mg/m² i.v., 3qw, 6 courses). Docetaxel-treated patients were reexamined at the inclusion hospital with new BM-analysis at approximately 1 month (BM3) and 13 months (BM4) after the last docetaxel infusion. Irrespective of the DTC-status at BM2, all patients are controlled at 6-12 months interval. Study overview is shown in Figure 1. Statistical analyses that include clinical outcome are first allowed after completion of follow-up and database lock. The follow-up is still ongoing.

Preparation of bone marrow mononuclear cell samples and detection of DTC
The BM was processed as described previously [20]. The BM-aspirates were pooled and separated by density centrifugation, mononuclear cells were collected and resuspended to 1×10⁶ cells/ml. Cytospins were prepared by centrifugation of the BM mononuclear cells (MNC)
down to poly-L-lysine-coated glass slides (5 × 10^5 MNC/slide), air-dried over night and stored at -80°C until immunostaining.

Prior to immunostaining, the cytospins were fixed for 10 min in acetone. Briefly, four slides (totally 2 × 10^6 BM MNC) were incubated with the anti-cytokeratin monoclonal antibodies (mAbs) AE1 (Millipore, prod.no. MAB1612) and AE3 (Millipore, prod.no. MAB1611). In parallel, the same numbers of slides (2 × 10^6 BM MNC) were incubated with the same concentration of a negative control mAb of same isotype (IgG 1; MOPC21, Sigma, prod. no. M9269). The visualization step included incubation with polyclonal rabbit anti-mouse immunoglobulins followed by preformed complexes of alkaline phosphatase/monoclonal mouse anti-alkaline phosphatase (AAPAP detection system, Dako). The color reaction was developed by incubation with New Fuchsin solution containing naphtol-AS-BI phosphate and levamisole, and the slides were counterstained with hematoxylin for 30 seconds to visualize nuclear morphology.

The slides were screened by an automated microscopy screening device (Ariol SL50, Applied Imaging), or screened manually in light microscopy. Candidate immunopositive cells selected by the automated screening were reviewed by a pathologist (E.B.). Immunopositive cells with morphology compatible with tumor cells and/or lacking hematopoietic characteristics were recorded as positive, according to the recommended guidelines [10,12,21,22]. If morphologically similar cells were detected both in the specific test and in the corresponding negative control, the result was regarded as DTC-negative. In a different cohort [20], we have tested the prognostic significance of these “double positive cases”, and no difference in clinical outcome compared to DTC-negative cases was observed (unpublished observations). In case of indeterminate cell morphology a second pathologist was consulted and consensus obtained. In doubtful cases, 16 additional cytospins were analyzed by the same ICC method (8 slides stained with AE1/AE3 mAbs and 8 slides stained with the MOPC21 control mAb).

Analysis of primary tumor and axillary lymph node
Analysis of the primary tumors and the sentinel nodes/axillary lymph nodes were processed on a routine
diagnostic basis. Histological tumor type, tumor size, and nodal involvement were analyzed and the disease was staged according to the tumor-node-metastasis (TNM) system (Union Internationale Contre le Cancer 1997). Tumor grading was performed according to Elston and Ellis [23]. The ER, PR and HER2 analyses were performed at the participating hospitals as part of the primary diagnostics. Immunohistochemical analyses for ER and PR receptors in primary tumors were performed according to the standard procedure in Norway at the time of the study and considered positive if > 10% of tumor cells stained positive with anti-ER- and/or anti-PR antibodies. The HER2 analysis was introduced as part of clinical routine from about June 2005, in parallel with the inclusion of trastuzumab into the adjuvant treatment guidelines for HER2-positive patients. Accessible HER2 results of the patients enrolled from this time period on have been obtained.

Statistics
The SPSS software (version 18) was used for all statistical analyses. Chi-square-based tests were used for calculation of p-values for the association between baseline characteristics and bone marrow results. For all statistical calculations the Exact Sig. (2-sided) were used as follows: Fisher Exact test for variables with two categories; Linear-by-Linear Association for variables with more than two categories.

Results
Characteristics of the study and patients
The study overview and patient enrollment are illustrated in Figure 1 and the clinico-pathological features of the patients are shown in Table 1. The median age at inclusion was 48 years (range 23-69 years). Most of these patients had pT1c and pT2 tumors, (46.7% and 41.9% respectively) and the majority was grade 2 or 3 tumors (53.9% and 37.3% respectively). Infiltrating ductal carcinoma constituted 82.4% of the cases, while 9.8% were lobular carcinomas. Estrogen receptors were expressed in 75.2% of the cases, and 17.4% of the patients analyzed for HER2 (from June 2005) were positive. Lymph node status was negative in 43.3% of the patients. Of those with presence of axillary metastases 2/3 were pN1.

DTC detection at BM1 and BM2
Out of 1085 patients with a reported DTC result for both BM1 and BM2, 94 (8.7%) and 83 patients (7.6%) were BM1 and BM2 positive, respectively (Table 1). The concordance between BM1 and BM2 was 86.5%. Among the BM1 positive patients, only 15 (16.0%) were BM2 positive, a result that may be affected by the recent administration of the standard adjuvant chemotherapy. Moreover, a change from BM1 positive to BM2 negative DTC-status was observed in 82.4% (61/74) of the endocrine treated patients, in 87.5% (7/8) of the trastuzumab treated patients (4 of the patients were treated with both endocrine therapy and trastuzumab) and in 85.7% (6/7) of the patients that did not receive endocrine treatment or trastuzumab. Presence of DTCs at BM1 was significantly associated with lobular carcinoma (p = 0.02) and BM2-status (p = 0.004), and borderline significance was observed for pT-status (p = 0.06) and histological grade (p = 0.06). At BM2, DTC-status was associated with pN-status (p = 0.009), pT-status (p = 0.03) and lobular carcinoma (p = 0.03). At BM1 28.8% of the DTC-positive patients had ≥ 2 DTCs, and 12.8% harboured ≥ 3 DTCs. At BM2, ≥ 2 DTCs were detected in almost half (47.0%) of the patients, whereas 25.3% had ≥ 3 DTCs (Table 2).

DTC-monitoring and tumor characteristics in docetaxel treated patients
Patients with BM2 positivity received docetaxel treatment. BM-aspiration post-treatment was performed if at least 4 cycles with docetaxel were administered. A presentation of the absolute numbers of DTCs (categorized as 0, 1, 2, 3-9 or ≥10 DTCs) at BM2, BM3 and BM4 is shown in Additional file 1: Figure S1 and Additional file 2: Figure S1. At BM3 DTC-status turned negative in 59 of 71 cases (83.0%), and 53 of 64 were negative at BM4 (82.8%) (Table 3). In 19 of the patients BM-aspiration was not performed at BM3 and/or BM4, as explained in Figure 1. Of 72 patients categorized according to the last (of BM3 or BM4) performed BM-aspiration, only 15 (20.8%) had persistent DTCs after docetaxel treatment (Table 3). Of 17 patients with ≥ 3 DTCs before docetaxel treatment, only 5 patients were positive after treatment (29.4%).

Subgroup analyses of patients with persistent DTCs after treatment compared to those with negative DTC-status after treatment are shown in Table 4. The change to negative DTC-status was significantly associated with ductal carcinoma histology (p = 0.009). For the other clinico-pathological parameters there were no significant associations. Furthermore, as shown in Additional file 3: Table S2, patients with ≥ 3 DTCs before treatment (i.e. at BM2) who turned DTC-negative after treatment, had similar characteristics as all the patients achieving negative DTC-status.

For the patients with DTC presence at BM1 and/or BM2, the DTC results at all performed time points, together with the endocrine and trastuzumab treatment status, are listed in Additional file 4: Table S3.

Discussion
The present study is, to our knowledge, the first reported study to use DTC-status to select for and monitor secondary adjuvant chemotherapy intervention in breast cancer. The identification of high-risk patients
Table 1 Clinico-pathological data of the patients and BM-status at BM1 and BM2

|                      | All patients | BM1 neg | BM1 pos | BM2 neg | BM2 pos | P value | BM1 pos | BM2 pos | P value |
|----------------------|--------------|---------|---------|---------|---------|---------|---------|---------|---------|
| Number:              | n = 1090     | n = 991 | n = 94  | n = 1002| n = 83  |         |         |         |         |
| Age at inclusion (median): | 48 (range 23-69) |         |         |         |         |         |         |         |         |
| Menopausal status:   |              |         |         |         |         |         |         |         |         |
| Pre                  | 592 (55.7)   | 540 (91.5) | 50 (8.5) | 547 (92.7) | 43 (7.3) | 0.19    |         |         |         |
| Post                 | 325 (30.6)   | 287 (88.9) | 36 (11.1) | 296 (91.6) | 27 (8.4) |         |         |         |         |
| Unknown              | 146 (13.7)   | 138 (95.2) | 7 (4.8)  | 134 (92.4) | 11 (7.6) |         |         |         |         |
| Missing              | 27           | 26       | 1       | 25       | (92.4)  | 2       |         |         |         |
| Primary breast cancer surgery: |         |         |         |         |         | 1.00    | 0.29    |         |         |
| Mastectomy           | 424 (39.4)   | 384 (91.2) | 37 (8.8) | 384 (91.2) | 37 (8.8) |         |         |         |         |
| Lumpectomy           | 653 (60.6)   | 594 (91.2) | 57 (8.8) | 60612 (93.1) | 45 (6.9) |         |         |         |         |
| Missing              | 13           | 13       |         |         |         | 1       |         |         |         |
| pT-status:           |              |         |         |         |         | 0.06    | 0.03    |         |         |
| pT 1a + b            | 67 (6.3)     | 55 (82.1) | 12 (17.9) | 65 (97.0) | 2 (3.0)  |         |         |         |         |
| pT1c                 | 500 (46.7)   | 451 (90.7) | 46 (9.3) | 464 (93.4) | 33 (6.6) |         |         |         |         |
| pT2                  | 449 (41.9)   | 418 (93.3) | 30 (6.7) | 407 (90.8) | 41 (9.2) |         |         |         |         |
| pT3                  | 49 (4.6)     | 44 (91.7) | 4 (8.3)  | 43 (89.6) | 5 (10.4) |         |         |         |         |
| pT4                  | 6 (0.6)      | 6 (100)   | 0 (0)    | 5 (83.3) | 1 (16.7) |         |         |         |         |
| Missing              | 19           | 17       | 2       | 18       | 1        |         |         |         |         |
| pN-status:           |              |         |         |         |         | 0.59    | 0.009   |         |         |
| pN0                  | 462 (43.3)   | 424 (92.2) | 36 (7.8) | 428 (93.0) | 32 (7.0) |         |         |         |         |
| pN1                  | 455 (42.6)   | 408 (89.9) | 44 (9.7) | 424 (93.8) | 28 (6.2) |         |         |         |         |
| pN2                  | 99 (9.3)     | 93 (93.9) | 6 (6.1)  | 86 (86.9) | 13 (13.1)|         |         |         |         |
| pN3                  | 52 (4.9)     | 46 (88.5) | 6 (11.5) | 43 (82.7) | 9 (17.3) |         |         |         |         |
| Missing              | 22           | 20       | 2       | 21       | 1        |         |         |         |         |
| Histology:           |              |         |         |         |         | 0.02e   | 0.03e   |         |         |
| IDC                  | 888 (82.4)   | 815 (92.3) | 68 (7.7) | 821 (93.0) | 62 (7.0) |         |         |         |         |
| ILC                  | 106 (9.8)    | 90 (84.9) | 16 (15.1)| 92 (86.8) | 14 (13.2)|         |         |         |         |
| Others               | 84 (7.8)     | 74 (88.1) | 10 (11.9)| 79 (94.0) | 5 (6.0) |         |         |         |         |
| Missing              | 12           | 12       |         | 10       | 2        |         |         |         |         |
| Histological grade:  |              |         |         |         |         | 0.06    | 0.92    |         |         |
| Grade 1              | 83 (7.7)     | 75 (90.4) | 8 (9.6)  | 80 (96.4) | 3 (3.6)  |         |         |         |         |
| Grade 2              | 583 (53.9)   | 520 (89.8) | 59 (10.2) | 527 (91.0) | 52 (9.0) |         |         |         |         |
| Grade 3              | 404 (37.3)   | 378 (93.8) | 25 (6.2) | 376 (93.3) | 27 (6.7) |         |         |         |         |
| Unclassified         | 12 (1.2)     | 117 (91.7) | 1 (8.3)  | 12 (100) | 0 (0) |         |         |         |         |
| Missing              | 8            | 1        |         | 7        | 1        |         |         |         |         |
| ER-status:           |              |         |         |         |         | 0.20    | 0.69    |         |         |
| Pos                  | 814 (75.2)   | 737 (91.0) | 73 (9.0) | 749 (92.5) | 61 (7.5) |         |         |         |         |
| Neg                  | 268 (24.8)   | 250 (93.6) | 17 (6.4) | 245 (91.8) | 22 (8.2) |         |         |         |         |
| Missing              | 8            | 4        |         | 4        | 8        |         |         |         |         |
| PR-status:           |              |         |         |         |         | 0.34    |         |         |         |
| Pos                  | 701 (64.9)   | 636 (91.1) | 62 (8.9) | 648 (92.8) | 50 (7.2) |         |         |         |         |
| Neg                  | 369 (34.2)   | 337 (91.6) | 310 (8.4) | 3359 (91.0) | 33 (90) |         |         |         |         |
| Unclassified         | 10 (1.0)     | 9 (100) | 1 (0) | 10 (100) | 0 (0) |         |         |         |         |
| Missing              | 10           | 9        |         |         |         |         |         |         |         |
for future relapse, at a time point where otherwise no additional prognostic information can be achieved from standard histopathological/clinical assessment, is attractive. This opens for testing of alternative treatment strategies in a “window of opportunity” for potential eradication of minimal residual disease. The results show that persistent DTCs 8-9 months after 6 courses of FEC chemotherapy are changed to DTC-negativity in 79.2% of the cases following secondary treatment with docetaxel. This indicates a potential for docetaxel to eradicate minimal residual disease burden in high-risk patients. It cannot be excluded that presence of 1 DTC can be followed, by chance, by a negative result in the next test (Poisson distribution and/or methodological limitations). However, persistent negativity at two time points, and especially the fact that ¾ of the patients with ≥3 DTCs at BM2 turned negative at BM3/4, suggest a change in the tumor cell load after the intervention. The recent meta-analysis of 14 randomized clinical trials by Jean-Philippe Jacquin et al [24], support a clear additional effect of docetaxel-containing adjuvant chemotherapy to a non-taxane-containing regimen in patients with early stage breast cancer (HR 0.84 (95% CI 0.78-0.89; P < 0.001) for DFS and 0.86 (0.78-0.94; P < 0.001) for OS). The benefit is consistent across all patient subgroups, although proliferation status was not analyzed. These results may support an association between the docetaxel secondary adjuvant treatment and the reduction in DTC-positivity in our study.

The subgroup analysis shown in Table 4 reveals a significant difference in the fate of DTCs after docetaxel treatment according to histological tumor subtype. Half of the patients with lobular carcinoma had persistent DTCs, as compared to 15% of the ductal carcinoma patients. This observation is in line with a reported relative chemotherapy resistance for lobular carcinoma [25-27], and adds further support to the possibility of docetaxel-induced changes in the observed DTC-status. Furthermore, a higher fraction of patients with DTC-positive status at BM1 seemed to have persistence of DTCs after the treatment, although statistical significance was not reached (p = 0.11). It may be speculated whether a proportion of these patients have a more resistant disease (i.e. less fluctuations of DTCs despite chemotherapy). It is known from several studies that patients with primary resistance to first line chemotherapy also have a higher risk of not responding to second line treatment [28,29]. The clinical outcome of the patients included in the present study needs to be awaited, before further interpretation of the results.

### Table 2: Number of DTCs detected in BM1 and BM2 positive cases

| Number of DTCs | BM1 Number (%) | BM2 Number (%) |
|---------------|----------------|----------------|
| 1             | 67 (71.3)      | 44 (53.0)      |
| 2             | 15 (16.0)      | 18 (21.7)      |
| 3-9           | 9 (9.6)        | 12 (14.5)      |
| ≥10           | 3 (3.2)        | 9 (10.8)       |
analyzing DTC-status 3 years after diagnosis [12]. In this previous study it was also observed that DTC-positivity was positively associated with lobular carcinoma, which can be explained by a relative resistance also to the anthracycline-containing chemotherapy [25,30]. Our study supports the selection of higher stage patients into future DTC intervention trials (Table 1), in order to select those with both the traditionally highest risk of relapse and the highest frequency of DTC-positivity. A consideration of the histological type may also be of importance, for selection to the proper type of systemic treatment to the right tumor subtype.

The testing of novel therapeutical principles or drugs is highly resource demanding. In addition, the effect of a new adjuvant treatment can only be evaluated when a relapse occurs, often several years later. The need for surrogate/intermediate markers to predict and monitor the therapeutic effect is obvious, but needs to be thoroughly validated. The present study is an initial step to explore the possibility to use DTCs in BM as a monitoring tool. Other possible approaches could be monitoring of circulating tumor cells (CTCs) or, as very recently reported, analysis of circulating tumor DNA in plasma/serum [31]. Detection of CTCs was not a part of the current study, because no standardized CTC-method was available at the time of study start. The performed repeated BM-analyses, however, were feasible and acceptable for the large majority of the patients.

The observed frequency of DTCs in the BM was markedly lower than what was expected prior to the study. This might be due to the assay sensitivity, but may have several additional explanations. The previously reported studies of DTCs have mostly been performed on BM-aspirates at the time of primary surgery. The subsequent administration of adjuvant chemotherapy might give a reduction in DTC-positivity. Furthermore, recent studies, using more standardized criteria, generally have shown lower DTC-positivity rates [12,20,22,32,33] than those reported in older studies. Additionally, there has been a stage migration after introduction of organized mammography screening (which is established in Norway), which probably results in less patients with micrometastatic disease. In our study, all the patients were screened for metastases before inclusion, which also might have affected the frequency of DTC presence. Finally, we used a conservative approach for inclusion of patients to docetaxel treatment in the current study. Doubtful cases were concluded as DTC-negative. It is possible to increase the sensitivity by analyzing larger number of cells (higher BM-volume). However, the clinical significance of DTC-status at primary surgery was not increased by analyzing more cells in our previous study [34]. Use of larger volumes of BM, or larger numbers of BM MNC, might require additional characterization of the detected DTCs, in order to identify markers of DTC aggressiveness and to secure both sensitivity and specificity. Accordingly, available FISH, CGH and multi-marker analyses may improve the utility of DTCs as a surrogate marker for response [33,35-39]. Characterization of the DTCs also opens for studies of tumor dormancy, EMT, stemness and/or identification of treatment targets.

The present study does not allow a direct interpretation of the effect of docetaxel on DTC-status. Although a randomized approach would have been the optimal design for this purpose, we chose the current design to explore the clinical potential for DTC-directed intervention. A randomized trial would raise several concerns, if performed unblinded to the DTC-status. To inform the patients about a DTC-positivity without intervention (in one arm) was considered ethically difficult. A blinded study (blinded randomization of both DTC-negative and DTC-positive patients to no additional versus docetaxel treatment) was found to be premature without supporting data and would have needed a very large and expensive study. Recently a randomized trial was reported for DTC positive early breast cancer patients at diagnosis, where patients received chemotherapy +/- zoledronic acid. The results showed improved elimination of DTCs in patients treated with zoledronic acid [40]. In another study in locally advanced breast cancer, DTC status was also affected by the administration of zoledronic acid [41]. Although clinical outcome results have not yet been reported, these data support the potential use of DTCs as a monitoring tool. In our study,

Table 3 Number of DTCs detected before (BM2) and after docetaxel treatment (BM3/BM4) in BM2-positive patients

| Number of DTCs | BM2 Number (%) | BM3 Number (%) | BM4 Number (%) | Last post-treatment BM result Number (%) |
|----------------|----------------|----------------|----------------|----------------------------------------|
| 0              | 59 (83.1)      | 53^ (82.8)     | 57 (79.2)      |                                        |
| 1              | 39 (54.1)      | 7 (9.9)        | 9 (14.1)       | 9 (12.5)                               |
| 2              | 16 (22.2)      | 1 (1.4)        | 1 (1.6)        | 2 (2.8)                                |
| ≥3             | 17 (23.6)      | 4 (5.6)        | 1 (1.6)        | 4 (5.6)                                |
| Not performed  | 1              | 8              |                |                                        |

^Only patients with DTC results at BM3 and/or BM4 are included (see Figure1).  
^Three samples classified as negative with morphologically similar cells detected in the corresponding negative control.
comparison to clinical end points has to await completion of the follow-up.

We chose 8-9 months after the standard adjuvant chemotherapy as time point for the DTC-analysis decisive for secondary adjuvant treatment. This was partially based on the results of the SBG study [13], where a positive DTC-status 6 months after chemotherapy identified patients with very poor prognosis. Furthermore, Slade et al performed repetitive BM-analyses at follow-up and found that the frequency of DTC-positive events was highest at 12 months after surgery [19]. Considering the increasing support for a detrimental outcome of patients with a positive DTC-status at later time points during follow-up [11], it might be an even more optimal approach to perform serial BM-aspirations during the first follow-up years, and to test secondary intervention

| Table 4 Analyses of clinico-pathological data and DTC-status after treatmenta |
|-----------------|----------------|----------------|----------------|----------------|
|                 | All patients | Persistent DTC | Negative for DTC |      |
|                 | Number (%)   | after treatment | after treatment |      |
|                 | n=72         | Number (%)     | Number (%)     |      |
| pT-status:      |              |                |                |      |
| pT1a +b         | 2 (2.8)      | 0 (0)          | 2 (100)        |      |
| pT1c            | 29 (40.3)    | 6 (20.7)       | 23 (79.3)      | 0.80 |
| 2pT2            | 41 (56.9)    | 9 (22.0)       | 32 (78.0)      |      |
| Histology:      |              |                |                |      |
| IDC             | 54 (76.1)    | 8 (14.8)       | 46 (85.2)      |      |
| ILC             | 14 (19.7)    | 7 (50.0)       | 7 (50.0)       | 0.009 |
| Others          | 3 (4.2)      | 0 (0)          | 3 (100)        |      |
| ER-status:      |              |                |                |      |
| Pos1            | 54 (75.0)    | 13 (24.1)      | 41 (75.9)      | 0.33 |
| Neg             | 18 (25.0)    | 2 (11.1)       | 16 (88.9)      |      |
| PR-status:      |              |                |                |      |
| Pos2            | 46 (63.9)    | 8 (17.4)       | 38 (82.6)      | 0.38 |
| Neg             | 26 (36.1)    | 7 (26.9)       | 19 (73.1)      |      |
| BM1:            |              |                |                |      |
| Pos             | 13 (18.1)    | 5 (38.5)       | 8 (61.5)       | 0.11 |
| Neg             | 59 (81.9)    | 8 (14.5)       | 47 (85.5)      |      |
| pN-status:      |              |                |                |      |
| pN0             | 28 (39.4)    | 4 (14.3)       | 24 (85.7)      | 0.37 |
| pN+             | 43 (60.6)    | 11 (25.6)      | 32 (74.4)      |      |
| Missing         | 1 0          | 1              |                |      |
| Histological grade: |          |                |                |      |
| Grade1-2        | 51 (71.8)    | 12 (23.5)      | 39 (76.5)      | 0.53 |
| Grade3          | 20 (28.2)    | 3 (15.0)       | 17 (85.0)      |      |
| Missing         | 1 0          | 1              |                |      |
| HER2-status:b   |              |                |                |      |
| Pos             | 6 (15.8)     | 0 (0)          | 6 (100)        | 0.57 |
| Neg             | 32 (84.2)    | 7 (21.9)       | 25 (78.1)      |      |
| Missing         | 1 0          | 1              |                |      |

aOnly patients with DTC results at BM3 and/or BM4 are included (see Figure 1).
bValid percent.
cThe percentages in relation to the clinico-pathological variables.
fFisher exact.
gComparison of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).
hPatients with positive ER and/or PR-status received endocrine treatment.
iPatients enrolled from June 2005 (n = 39). Patients with positive HER2-status received trastuzumab.
whenever a DTC-positive status appear. This might be a reasonable consideration for future studies.

Conclusions
DTC-analysis can be a useful tool for identifying patients who do not respond to a chosen standard adjuvant therapy and accordingly should be tested for benefit of additional secondary adjuvant therapy. Elimination of DTCs after docetaxel treatment was observed in the majority of the patients. Although the clinical significance of these results awaits mature follow-up data, the current study presents a novel potential approach for optimized adjuvant treatment of breast cancer, supporting further exploration of this intervention principle.

Additional files

Additional file 1: Figure S1. Number of DTCs detected in BM2-positive, docetaxel treated patients, at BM2, BM3 and BM4.

Additional file 2: Table S1. Complete DTC-status at all time points for BM2-positive patients.

Additional file 3: Table S2. Analyses of clinico-pathological data and DTC-status after treatment for patients with ≥ 3 DTCs at BM2.

Additional file 4: Table S3. Presentation of DTC status at all performed time points, endocrine treatment and trastuzumab treatment status for BM1 and/or BM2 positive patients.

Abbreviations
DTC: Disseminated tumor cell; BM: Bone marrow; pN1-3 and pT1c/T2G2-3pN0: Standard tumor-node-metastasis (TNM) classification according to AJCC/UICC 2002; 3qw: Every third week; EMT: Epithelial-mesenchymal transition; CGH: Comparative genomic hybridization; multi-marker IF: Multi-marker immunofluorescence; pN1-3: Metastasis to 1-3 axillary lymph nodes; HR: Hazard ratio; CI: Confidence interval; DFS: Disease free survival; OS: Overall survival; FISH: Fluorescence in situ hybridization; CGH: Comparative genomic hybridization; EMT: Epithelial-mesenchymal transition; SBG: Scandinavian Breast Group.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BN was head of study. MS, BN and EB drafted the manuscript. MS and BN performed the data analysis and carried out the statistics. BN and EW were responsible for study design. MS, EW, GW, KW, TR, CK, IM and BN were responsible for enrollment of patients. EB and JMN scored/classified the detected cells. CBS was responsible for the automated screening; EB performed the manual screening. All authors read and approved the final manuscript.

Acknowledgements
We thank the staff at The Micrometastasis Laboratory, Department of Pathology, Radiumhospitalet, for their excellent technical assistance. We also thank, Ivar Guldfog (Telemark Hospital), Nina Podhrody (Drammen Hospital), Karin Semb (Vestfold Hospital), Hans Aas (Vestfold Hospital), Leiv S. Rusten (Drammen Hospital), Berit Gravdahau (Akershus University Hospital), and the study nurses (Mette Stokke, Maria F. Dahlen, Pernille B. Sørensen, Anne K. Reiset, Kristin I. Jensen, Åse M. Thuen, Benedt M. Christensen, Randi Bjeleik, Aud O. Løkken) at the different hospitals for importantly assisting in the inclusion and follow-up of the patients. The study was supported by The Research Council of Norway, South-Eastern Norway Regional Health Authority, The Norwegian Cancer Society, K. G. Jebsen Centre for Breast Cancer Research and Sandi.

Received: 1 November 2012 Accepted: 18 December 2012
Published: 22 December 2012

References
1. Braun S, Ktenenich C, Janin W, Hepp F, de Wall J, Willigeroth F, Sommer H, Pantel K: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000, 18:880–886.
2. Deaneley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC, Clink HM, Powles TJ, Ford HT, Gazet JC, Neville AM: Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer 1981, 44:85–90.
3. Hess MM, Allgayer H, Gratzinger KJ, Funke I, Babin J, Jauch KW, Schildberg FW: Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995, 1:1035–1039.
4. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, Backmann R, Funke I, Riethmueller G: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991, 51:4712–4715.
5. Pantel K, Schlimok G, Angstmu B, Weckermann D, Schinas W, Gath H, Paslick B, Ibbitsch JK, Riethmueller G: Methodological analysis of immunocytocchemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994, 3:165–173.
6. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade, Nat Rev Cancer 2004, 4:448–456.
7. Schlimok G, Funke I, Holzbm B, Gottlinger G, Schmidt G, Hauser H, Sweekott S, Warnecke HH, Schneider B, Koprivski H: Micrometastatic cancer cells in bone marrow: in vitro detection with antibody- cytoketin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci USA 1987, 84:8652–8667.
8. Schlimok G, Pantel K, Lobnner H, Fackler-Schwalbe I, Riethmueller G: Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 1995, 31A:1799–1803.
9. Sloane JP, Ormerod MG, Neville AM: Potential pathological application of immunocytocchemical methods to the detection of micrometastases. Cancer Res 1980, 40:3079–3082.
10. Fehm T, Braun S, Muller V, Janin W, Gebauer G, Marth C, Schindebeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E: A concept for the standardization of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006, 107:885–892.
11. Janin W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Juckstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B: Persistence of disseminated tumor cells in the bone...
morrow of breast cancer patients predicts increased risk for relapse—a European pooled analysis. Clin Cancer Res 2011, 17:2967–2976.

12. Wiedswang G, Borgen E, Karesen R, Quist H, Janbu J, Kvåleheim G, Nesland JM, Naume B: Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004, 10:5342–5348.

13. Draguet J, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvåleheim G: Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. Int J Cancer 2006, 118:2877–2881.

14. Fumdeo P, Chevalier B, Kerbrat P, Krokowski Y, Misset JL, Maujard-Louboutin C, Dieser V, Adi N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996, 7:165–171.

15. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Spival M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999, 35:1194–1201.

16. Smith IC, Heys SD, Hutchesson AM, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremon O, Walker LG, Sarkar TK, Eggett SP, Ostnow KN: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with Docetaxel. J Clin Oncol 2002, 20:1456–1466.

17. Nabholtz JM, Gligorov J: Taxane therapy for early stage breast cancer. Womens Health (Lond Engl) 2006, 2:59–114.

18. Martin M, Penkivski T, Mackay J, Pawlicki M, Chevallier B, Kerbrat P, Tak, Lu, Hu, Relin, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Alix-Panabieres C, Schwarzenbach H, Pantel K: Monitoring of disseminated tumor cells of patients with breast cancer: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008, 14:3306–3311.

19. Hartkopf AD, Banyas M, Fein F: HER2-positive DTCs/CTCs in breast cancer. Recent Results Cancer Res 2012, 193:203–215.

20. Wiedswang G, Borgen E, Karesen R, Naume B: Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed. Cytogenetics 2003, 5:40–45.

21. Balic M, Rapp N, Stanzler S, Lin H, Stratuz J, Szakendra J, Daidone MG, Sammonig H, Cote RJ, Dandachi N: Novel immunohistochemical protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol 2011, 19:83–90.

22. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D, Becker S: E-rlapha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008, 10:R76.

23. Fuhrmann C, Schmidt-Axthel O, Steckle K, Piatt-Dutter K, Van C, Bockler K, Reinhardt R, Ragg T, Klein C: High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucl Acids Res 2008, 36:6039.

24. Mathiesen RR, Fjelldal R, Liestol K, Due EU, Geigl JB, Riethdorf S, Borgen E, Mathiesen RR, Fjelldal R, Liestol K, Due EU, Geigl JB, Riethdorf S, Borgen E, Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D, Becker S: E-rlapha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008, 10:R76.

25. Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Alix-Panabieres C, Schwarzenbach H, Pantel K: Monitoring of disseminated tumor cells of patients with breast cancer: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008, 14:3306–3311.

26. Wiedswang G, Borgen E, Karesen R, Naume B: Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed. Cytogenetics 2003, 5:40–45.

27. Balic M, Rapp N, Stanzler S, Lin H, Stratuz J, Szakendra J, Daidone MG, Sammonig H, Cote RJ, Dandachi N: Novel immunohistochemical protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol 2011, 19:83–90.

28. van Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huebner J, Costa SD, Jakisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine-capetabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008, 100:542–551.

29. van Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huebner J, Costa SD, Jakisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine-capetabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008, 100:542–551.

30. Brunello E, Brunelli M, Manfrin E, Nottegag A, Bersani S, Vergine M, Molino A, Fiorio E, Chiosis M, Bobbi S, Martignoni G, Bonetti F: Classical lobular breast carcinoma consistently lacks topoisomerase-I/filp kinase gene amplification: implications for the tailored use of anthracycline-based chemotherapies. Histopathology 2012, 60:482–488.

31. Elston CW, Ellis IO: Breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2007, 8:1139–1147.

32. Bidard FC, Vincent-Salomon A, Gamme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sebban C: Detection of disseminated tumor cells in bone marrow of breast cancer patients: a strong prognostic factor for distant and local relapse. Ann Surg 2008, 248:808–813.

33. Hartkopf AD, Banyas M, Fein F: HER2-positive DTCs/CTCs in breast cancer. Recent Results Cancer Res 2012, 193:203–215.

34. Wiedswang G, Borgen E, Karesen R, Naume B: Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed. Cytogenetics 2003, 5:40–45.

35. Balic M, Rapp N, Stanzler S, Lin H, Stratuz J, Szakendra J, Daidone MG, Sammonig H, Cote RJ, Dandachi N: Novel immunohistochemical protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol 2011, 19:83–90.

36. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D, Becker S: E-rlapha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008, 10:R76.

37. Fuhrmann C, Schmidt-Axthel O, Steckle K, Piatt-Dutter K, Van C, Bockler K, Reinhardt R, Ragg T, Klein C: High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucl Acids Res 2008, 36:6039.

38. Mathiesen RR, Fjelldal R, Liestol K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider U, Obenauf AC, Mauerman O, Nilsen G, Christian LO, Boresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO: High-resolution analysis of copy number changes in disseminated tumor cells of patients with breast cancer. Int J Cancer 2011, 131:E405–E415.

39. Vincent-Salomon A, Pierga JY, Couturier J, D'Enghien CD, Nos C, Sigal-Zafrani B, Loeve I, Zaidi M, Gilbanners W, Piatut D, Mortimer J, Weilbaecher K: Effect of zolendronic acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421–428.

Cite this article as: Synnestvedt et al.: Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study. Breast Cancer Res 2012, 14:616.